Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TBX2 is a neuroblastoma core regulatory circuitry component enhancing MYCN/FOXM1 reactivation of DREAM targets.
Decaesteker B, Denecker G, Van Neste C, Dolman EM, Van Loocke W, Gartlgruber M, Nunes C, De Vloed F, Depuydt P, Verboom K, Rombaut D, Loontiens S, De Wyn J, Kholosy WM, Koopmans B, Essing AHW, Herrmann C, Dreidax D, Durinck K, Deforce D, Van Nieuwerburgh F, Henssen A, Versteeg R, Boeva V, Schleiermacher G, van Nes J, Mestdagh P, Vanhauwaert S, Schulte JH, Westermann F, Molenaar JJ, De Preter K, Speleman F. Decaesteker B, et al. Among authors: koopmans b. Nat Commun. 2018 Nov 19;9(1):4866. doi: 10.1038/s41467-018-06699-9. Nat Commun. 2018. PMID: 30451831 Free PMC article.
Preclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia.
Wander P, Cheung LC, Pinhanҫos SS, Jones L, Kerstjens M, Arentsen-Peters STCJM, Singh S, Chua GA, Castro PG, Schneider P, Dolman MEM, Koopmans B, Molenaar JJ, Pieters R, Zwaan CM, Kotecha RS, Stam RW. Wander P, et al. Among authors: koopmans b. Leukemia. 2020 Nov;34(11):2898-2902. doi: 10.1038/s41375-020-0895-9. Epub 2020 Jun 2. Leukemia. 2020. PMID: 32488115 No abstract available.
High-throughput drug screening reveals Pyrvinium pamoate as effective candidate against pediatric MLL-rearranged acute myeloid leukemia.
Wander P, Arentsen-Peters STCJM, Pinhanҫos SS, Koopmans B, Dolman MEM, Ariese R, Bos FL, Castro PG, Jones L, Schneider P, Navarro MG, Molenaar JJ, Rios AC, Zwaan CM, Stam RW. Wander P, et al. Among authors: koopmans b. Transl Oncol. 2021 May;14(5):101048. doi: 10.1016/j.tranon.2021.101048. Epub 2021 Mar 2. Transl Oncol. 2021. PMID: 33667892 Free PMC article.
High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells.
Vernooij L, Bate-Eya LT, Alles LK, Lee JY, Koopmans B, Jonus HC, Schubert NA, Schild L, Lelieveld D, Egan DA, Kerstjens M, Stam RW, Koster J, Goldsmith KC, Molenaar JJ, Dolman MEM. Vernooij L, et al. Among authors: koopmans b. Mol Cancer Ther. 2021 Jun;20(6):1161-1172. doi: 10.1158/1535-7163.MCT-20-0666. Epub 2021 Apr 13. Mol Cancer Ther. 2021. PMID: 33850004 Free PMC article.
Defects in 8-oxo-guanine repair pathway cause high frequency of C > A substitutions in neuroblastoma.
van den Boogaard ML, Oka R, Hakkert A, Schild L, Ebus ME, van Gerven MR, Zwijnenburg DA, Molenaar P, Hoyng LL, Dolman MEM, Essing AHW, Koopmans B, Helleday T, Drost J, van Boxtel R, Versteeg R, Koster J, Molenaar JJ. van den Boogaard ML, et al. Among authors: koopmans b. Proc Natl Acad Sci U S A. 2021 Sep 7;118(36):e2007898118. doi: 10.1073/pnas.2007898118. Proc Natl Acad Sci U S A. 2021. PMID: 34479993 Free PMC article.
High-Throughput Drug Library Screening in Primary KMT2A-Rearranged Infant ALL Cells Favors the Identification of Drug Candidates That Activate P53 Signaling.
Wander P, Arentsen-Peters STCJM, Vrenken KS, Pinhanҫos SM, Koopmans B, Dolman MEM, Jones L, Garrido Castro P, Schneider P, Kerstjens M, Molenaar JJ, Pieters R, Zwaan CM, Stam RW. Wander P, et al. Among authors: koopmans b. Biomedicines. 2022 Mar 10;10(3):638. doi: 10.3390/biomedicines10030638. Biomedicines. 2022. PMID: 35327440 Free PMC article.
Chromosome 11q loss and MYCN amplification demonstrate synthetic lethality with checkpoint kinase 1 inhibition in neuroblastoma.
Keller KM, Eleveld TF, Schild L, van den Handel K, van den Boogaard M, Amo-Addae V, Eising S, Ober K, Koopmans B, Looijenga L, Tytgat GAM, Ylstra B, Molenaar JJ, Dolman MEM, van Hooff SR. Keller KM, et al. Among authors: koopmans b. Front Oncol. 2022 Sep 27;12:929123. doi: 10.3389/fonc.2022.929123. eCollection 2022. Front Oncol. 2022. PMID: 36237330 Free PMC article.
Epigenetic modulation of neuroblastoma enhances T cell and NK cell immunogenicity by inducing a tumor-cell lineage switch.
Cornel AM, Dunnebach E, Hofman DA, Das S, Sengupta S, van den Ham F, Wienke J, Strijker JGM, van den Beemt DAMH, Essing AHW, Koopmans B, Engels SAG, Lo Presti V, Szanto CS, George RE, Molenaar JJ, van Heesch S, Dierselhuis MP, Nierkens S. Cornel AM, et al. Among authors: koopmans b. J Immunother Cancer. 2022 Dec;10(12):e005002. doi: 10.1136/jitc-2022-005002. J Immunother Cancer. 2022. PMID: 36521927 Free PMC article.
MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma.
Eleveld TF, Vernooij L, Schild L, Koopmans B, Alles LK, Ebus ME, Dandis R, van Tinteren H, Caron HN, Koster J, van Noesel MM, Tytgat GAM, Eising S, Versteeg R, Dolman MEM, Molenaar JJ. Eleveld TF, et al. Among authors: koopmans b. Front Oncol. 2023 Feb 21;13:1130034. doi: 10.3389/fonc.2023.1130034. eCollection 2023. Front Oncol. 2023. PMID: 36895472 Free PMC article.
109 results